The PILLAR Study

The World Health Organisation estimates that 65 million people worldwide have moderate to severe COPD. Although maintenance therapies are available to help maintain regular breathing, some people still have symptoms or experience exacerbations which can result in a hospital admission, even when prescribed a combination of all three therapies.

We are taking part in the PILLAR study which aims to understand whether a new investigational add-on medication will reduce airway inflammation and improve COPD symptoms in people on maintenance triple therapy.

The study is recruiting male and female participants over the age of 40 years, with an established diagnosis of COPD. To be eligible for this study participants will have had chronic bronchitis for at least three months in each of the prior two consecutive years, or had a chronic productive cough within the previous year.

We are working with our research technology partner uMed to invite patients to this study. If you meet the study criteria, you may receive a text message, email or letter asking whether you would like to take part. Participation is entirely voluntary and you can opt out at any time.